Scientists have isolated more than 113 distinct cannabinoids from the cannabis plant, and the count continues to grow as analytical tools improve. These compounds fall into roughly 11 chemical sub-classes, but only a handful appear in significant concentrations. The rest exist in trace amounts, many discovered only in the last few years.
The 11 Chemical Classes
Those 113-plus cannabinoids aren’t 113 totally different molecules doing 113 different things. They cluster into chemical families based on shared structures: cannabigerols (CBG types), cannabichromenes (CBC types), cannabidiols (CBD types), delta-9-tetrahydrocannabinols (THC types), delta-8-tetrahydrocannabinols, cannabicyclols, cannabielsoins, cannabinols (CBN types), cannabinodiols, cannabitriols, and a catch-all “miscellaneous” group. Within each family, individual compounds differ by small structural tweaks like side-chain length or the presence of an acid group.
Major vs. Minor Cannabinoids
Of the 113-plus identified cannabinoids, only a small number show up in meaningful quantities. THC and CBD are the two most abundant, and together with their acid forms (THCA and CBDA) and two other compounds, CBC and CBG, they make up the bulk of what’s actually in the plant. Everything else falls into the “minor cannabinoid” category, meaning it occurs naturally at very low concentrations. This group includes compounds like CBN, THCV, CBDV, cannabielsoin (CBE), and cannabimovone (CBM).
Low concentration doesn’t mean unimportant. Several minor cannabinoids have shown distinct biological activity in early research. But from a practical standpoint, most cannabis flower is dominated by THC and CBD, with the rest making up only a small fraction of total cannabinoid content.
How the Plant Builds Cannabinoids
Cannabis doesn’t produce each cannabinoid independently. Nearly all of them trace back to a single precursor molecule called cannabigerolic acid (CBGA), sometimes called the “mother cannabinoid.” The plant uses three different enzymes to convert CBGA into three main branches: THCA, CBDA, and CBCA. From those three acid forms, the rest of the cannabinoid family tree unfolds through heat, light, oxygen exposure, and time.
This branching system explains why the total count is so high. Each core compound spawns variants through natural chemical reactions, and small structural differences (like a shorter carbon side chain) create technically distinct molecules with their own names and, sometimes, their own effects.
Acid Forms vs. Neutral Forms
One detail that inflates the cannabinoid count: the plant actually produces acid forms of cannabinoids, not the neutral versions most people recognize. Raw cannabis contains THCA, not THC. CBDA, not CBD. CBGA, not CBG. These acid forms don’t produce the same effects as their neutral counterparts.
The conversion happens through a process called decarboxylation, which is just a chemical reaction triggered by heat. When you smoke, vape, or bake cannabis, temperatures between roughly 80°C and 160°C (176°F to 320°F) strip a carbon dioxide molecule off the acid form, turning THCA into THC, CBDA into CBD, and so on. This is why eating raw cannabis flower won’t get you high the way smoking it does.
Cannabinoids That Form After Harvest
Not every cannabinoid in cannabis was made by the living plant. CBN, for example, isn’t produced by the plant’s own metabolism. It forms when THC breaks down through exposure to oxygen, light, and heat over time. Poorly stored or old cannabis tends to have higher CBN levels and lower THC levels for exactly this reason. Scientists consider elevated CBN a chemical indicator of lengthy or poor storage conditions.
Other post-harvest transformations include the conversion of THC types into delta-8-THC (a more thermodynamically stable form created by heat exposure) and cannabicyclols, which form when cannabichromenes are exposed to light. So the full roster of cannabinoids found in a given cannabis sample depends not just on the strain’s genetics but on how the product was processed and stored.
The Varin Series
One of the more interesting sub-groups is the “varin” series: THCV, CBDV, CBCV, and their acid forms. Structurally, these look almost identical to their more common counterparts, with one difference. They have a shorter carbon side chain (three carbons instead of five). That small change produces surprisingly different effects.
THCV is the best-studied example. For a long time, researchers assumed it was simply a weaker version of THC. Instead, it appears to work as an antagonist at the same receptors THC activates, essentially blocking rather than stimulating them. THCV has shown effects on lipid and glucose metabolism, and both THCV and CBDV have demonstrated anti-convulsant properties in early studies. These compounds occur naturally at very low levels in most cannabis strains, though breeders are working to develop cultivars with higher varin content.
Recently Discovered Cannabinoids
The count of 113 isn’t a fixed number. In 2019, a team of Italian researchers identified a cannabinoid called THCP (tetrahydrocannabiphorol), which has a longer side chain than THC instead of a shorter one. Early studies suggest THCP binds to the brain’s CB1 receptors with roughly 33 times the affinity of regular THC, potentially making it far more potent. Its natural concentration in cannabis appears to be extremely small, but its discovery raised questions about whether trace cannabinoids might contribute more to the overall experience of cannabis than previously thought.
THCP is just one example. As lab techniques become more sensitive, researchers continue to identify new cannabinoid structures in the plant. The total number referenced in scientific literature has been climbing for decades and shows no sign of plateauing.
Why CBD Doesn’t Get You High
With so many cannabinoids, it’s worth understanding why most of them don’t produce intoxication. THC works by directly activating CB1 receptors in the brain. CBD, the second most abundant cannabinoid, barely interacts with those receptors at all. According to a World Health Organization review, CBD shows no measurable binding to CB1 receptors in most studies, and even at high oral doses (200 mg), it produces no impairment of motor or mental performance, no increased heart rate, and no dry mouth.
CBD does interact with the body’s endocannabinoid system, just through indirect routes. It may act as a negative allosteric modulator of the CB1 receptor, which means it can dampen THC’s effects without activating the receptor itself. It also appears to boost levels of anandamide, one of the body’s own cannabinoid-like molecules, by slowing its breakdown. Beyond the endocannabinoid system, CBD influences serotonin receptors, adenosine signaling, and glycine receptors, which may explain its range of reported effects.
Most of the other 100-plus cannabinoids similarly lack the specific receptor interaction that makes THC intoxicating. The psychoactive experience of cannabis is driven overwhelmingly by THC, with THCP and a few close analogs as the only other known candidates for producing a high.